Skip to content
Gold Mining News – Lifestyle
Author:
Eisai Inc.
Eisai Deepens Its Oncology Evidence Base at ESMO Congress 2026
October 15, 2026
LEQEMBI IQLIK®(lecanemab-irmb) Autoinjector for Initiation of Therapy Now Available in the U.S. for Early Alzheimer’s Disease
August 29, 2026
LEQEMBI® Real-World LEADER Study Presented at AAIC® 2026 Finds Over 75% of Early Alzheimer’s Patients Enrolled in the Study Remained Stable and Nearly 7% Improved Over an Average of 17 Months of Treatment
July 14, 2026
LEQEMBI® Real-World LEADER Study Presented at AAIC® 2026 Finds Over 75% of Early Alzheimer’s Patients Enrolled in the Study Remained Stable and Nearly 7% Improved Over an Average of 17 Months of Treatment
July 14, 2026
FDA Approves LEQEMBI IQLIK® (lecanemab-irmb) Subcutaneous Injection as an Initiation Dose for Early Alzheimer’s Disease
July 13, 2026
Eisai Presents Latest Findings Showed Etalanetug Reduced Alzheimer’s Disease Tau Tangle-Specific Plasma Biomarker MTBR-tau243 at Alzheimer’s Association International Conference® (AAIC®) 2026
July 13, 2026
LEQEMBI® Subcutaneous Autoinjector Clinical Data Supports Similar Efficacy and Safety to IV Formulation in Early Alzheimer’s Disease Presented at the Alzheimer’s Association International Conference® (AAIC®) 2026
July 12, 2026
Eisai to Showcase Alzheimer’s Disease Portfolio with More Than 50 Presentations at the Alzheimer’s Association International Conference® 2026 (AAIC®)
June 29, 2026
Eisai and CaringKind Launch New Initiative to Address Mealtime and Nutrition Needs for People Living with Alzheimer’s Disease and Related Dementias
June 1, 2026
Update on FDA Priority Review of LEQEMBI® IQLIK™ (lecanemab-irmb) Subcutaneous Injection as a Starting Dose for Early Alzheimer’s Disease
May 8, 2026